Subscribe Sign In

Why register?

Home
News
Events
- Find an event
- Live event coverage
Deep Dive
Sales and marketing
Digital
Market Access
Oncology
Patients
R&D
Spotlight On
- Frontiers Health 2021
- The Future of Generics
Advertise

Search

Search

Close

Trending

Endo files for bankruptcy as it agrees opioid settlement

bluebird unveils $2.8m price for gene therapy Zynteglo on FDA approval

Diving deeper into AI discovery, Sanofi signs 5-drug deal with Atomwise

GSK gets June 2023 FDA decision date for momelotinib

End of the line for Sanofi’s SERD amcenestrant as it fails first-line trial

Insuline

Danish pharma company Novo Nordisk

Diabetes/ Diabetes/ News/ News/ News/ Novo Nordisk/ Patients/ R&D/ Top pharmaceutical companies/ Top stories

Novo’s diabetes pill beats injections in head-to-head trials

Piotr Wnuk Diabetes, diabetes care, GLP-1, Insuline, Januvia, Novo Nordisk, semaglutide, Sitagliptin, Type 2 diabetes, Victoza 0 Comment

Novo Nordisk is making the case for its diabetes pill, which it hopes will allow it to fight

X

Novo’s diabetes pill beats injections in head-to-head trials

https://pharmaphorum.com/news/novo-nordisks-success-with-oral-diabetes-drug/

Get in-depth news, opinions and features on pharma and healthcare sent straight to your inbox

Featured content

How to improve payer engagement with tailored value communication

How to improve payer engagement with tailored value communication

How will NICE fare in a post-Brexit world?

How will NICE fare in a post-Brexit world?

Events

MAPS 2018 EMEA Annual Meeting

MAPS 2018 EMEA Annual Meeting

Cell & Gene Therapy 2018

Cell & Gene Therapy 2018

Patient Engagement Event - a real world snapshot, beyond the talk

Patient Engagement Event - a real world snapshot, beyond the talk

Most popular

Most Viewed

GSK gets June 2023 FDA decision date for momelotinib
End of the line for Sanofi's SERD amcenestrant as it fails first-line trial
UK first to approve Moderna's Omicron booster jab
Strike three for Novartis' canakinumab as lung cancer therapy
On heels of new data, Gilead pays $455m for Asian Trodelvy rights

Tweets from @pharmaphorum

Tweets by @pharmaphorum

Advertise
pharmaphorum connect

Contribute
Work for pharmaphorum

About us
Contact us
Privacy policy
Terms & conditions
Cookie Policy

The rights of trade mark owners are acknowledged. pharmaphorum media limited

Website and content copyright © 2009-, pharmaphorum media limited or its licensors; all rights reserved.

© 2022

Powered by WordPress • Themify WordPress Themes

Login

Username or Email Address

Password

Remember Me

Lost your password?

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com